An overview of the diagnosis and management of MDS, including recent treatment, was discussed in a paper published in the American Journal of Hematology.
Most patients achieved deep remission after a 14-month regimen of obinutuzumab, ibrutinib, and venetoclax.
How to explain adjustments to cancer care due to the COVID-19 pandemic and ease patients’ fears about the impact of those changes.
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.
Practices need to know all of the components of their health information systems to determine potential vulnerabilities.